The study investigated the effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes.

RAS Rosiglitazone and Atherosclerosis Study: A 1 year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus

Inclusion criteria:

• insulin resistant syndrome or Type 2 Diabetes.

Exclusion criteria:

• Use of >= 2 concomitant oral antihyperglycaemic agents within 3 months of study start.
• Initiation of anti-hypertensive or lipid lowering therapy <= 6 months prior to study start or who increased the dose 3 months prior to study start.
• Unstable or severe angina or congestive heart failure NYHA class i-iv, history of acute myocardial infarction or stroke within last 6 months.
• Any history of surgical intervention in the right carotid artery.
• Clinically significant hepatic disease.
• Creatinine clearance <40ml/min.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.